Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $483.16, for a total transaction of $4,010,228.00. Following the transaction, the executive vice president owned 36,844 shares of the company’s stock, valued at approximately $17,801,547.04. This represents a 18.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Stock Down 1.1%

Shares of UTHR stock traded down $5.15 during trading hours on Thursday, reaching $485.06. The company’s stock had a trading volume of 420,755 shares, compared to its average volume of 381,036. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $537.19. The firm’s 50 day simple moving average is $483.67 and its 200-day simple moving average is $450.90. The company has a market capitalization of $21.26 billion, a price-to-earnings ratio of 17.39, a PEG ratio of 1.79 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.United Therapeutics’s revenue was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $6.19 EPS. Sell-side analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on UTHR shares. HC Wainwright raised their price target on shares of United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Bank of America reaffirmed a “neutral” rating on shares of United Therapeutics in a research note on Wednesday, February 25th. UBS Group upped their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Monday. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $539.00.

Institutional Investors Weigh In On United Therapeutics

Institutional investors have recently made changes to their positions in the stock. AXQ Capital LP raised its stake in United Therapeutics by 495.4% in the 2nd quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock valued at $1,117,000 after acquiring an additional 3,235 shares during the period. AE Wealth Management LLC boosted its position in United Therapeutics by 396.3% during the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after purchasing an additional 3,424 shares during the period. Great Lakes Advisors LLC increased its stake in shares of United Therapeutics by 194.7% in the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after purchasing an additional 2,975 shares in the last quarter. Optimize Financial Inc bought a new stake in shares of United Therapeutics in the third quarter valued at approximately $444,000. Finally, Simplify Asset Management Inc. purchased a new stake in shares of United Therapeutics during the 3rd quarter valued at approximately $8,351,000. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.